Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Brain Tumor

• Status: Withdrawn
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells.

PURPOSE: Phase II trial to study the effectiveness of different regimens of combination chemotherapy followed by peripheral stem cell transplantation in treating children who have newly diagnosed brain tumor.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: New York University School of Medicine; NYU Langone Health
• Treatments: Carboplatin; Cyclophosphamide; Etoposide; Etoposide phosphate; Leucovorin; Levoleucovorin; Methotrexate; Temozolomide; Thiotepa; Vincristine

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed malignant, newly diagnosed brain tumor

Regimen A:

• Posterior fossa medulloblastoma/primitive neuroectodermal tumor (PNET):

• All stages, under 3 years at diagnosis OR

• High stage (local residual tumor postoperatively and/or neuraxis or extraneural dissemination), 3-10 years at diagnosis

• Supratentorial PNET, pineoblastoma, cerebral neuroblastoma, ependymoblastoma, medulloepithelioma, medullomyoblastoma:

• All stages, under 10 years at diagnosis

• Brainstem PNET:

• All stages, irrespective of extent of resection, under 10 years at diagnosis

• Ependymoma or anaplastic ependymoma:

• All stages, any location (except primary spinal cord ependymoma), under 3 years at diagnosis OR

• Local residual tumor postoperatively and/or neuraxis dissemination, any location, 3-10 years at diagnosis

• Supratentorial ependymoma:

• All stages, irrespective of extent of resection, under 10 years at diagnosis, excluding gross totally resected (confirmed by postoperative MRI) low grade ependymoma not invading the ventricular system

• Metastatic retinoblastoma:

• Previously untreated (except for cryosurgery or laser surgery), under 10 years at presentation of metastatic disease

• Primary atypical teratoid/rhabdoid tumors of the CNS:

• Under 10 years at diagnosis

• Choroid plexus carcinoma:

• Incompletely resected, all sites, under 10 years at diagnosis

Regimen C:

• Anaplastic astrocytoma, glioblastoma multiforme, anaplastic oligodendroglioma, anaplastic ganglioglioma, other anaplastic mixed gliomas:

• Under 10 years at diagnosis

• Diffuse intrinsic pontine tumors:

• Unbiopsied, under 10 years at diagnosis

The following diagnoses are not eligible:

• Myxopapillary ependymoma of the spinal cord, low grade brainstem astrocytoma, primary CNS lymphoma or solid leukemic lesion (i.e., chloroma, granulocytic sarcoma), or primary CNS germ cell tumor

PATIENT CHARACTERISTICS:

Age:

• Under 10 at diagnosis

Performance status:

• Not specified

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• Bilirubin less than 1.5 mg/dL

• SGPT less than 2.5 times upper limit of normal

Renal:

• Creatinine clearance greater than 60 mL/min

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• Not specified

Chemotherapy:

• No prior chemotherapy

Endocrine therapy:

• Prior corticosteroids allowed

• No concurrent corticosteroids for the sole purpose of antiemesis

Radiotherapy:

• No prior radiotherapy

Surgery:

• See Disease Characteristics

• Recovered from prior surgery